Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2

Next Previous
Trial Profile

An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alixorexton (Primary)
  • Indications Idiopathic hypersomnia; Narcolepsy
  • Focus Adverse reactions; Registrational
  • Sponsors Alkermes plc

Most Recent Events

  • 02 Jul 2025 Planned End Date changed from 1 Nov 2027 to 1 Jun 2028.
  • 02 Jul 2025 Planned primary completion date changed from 1 Nov 2027 to 1 Jun 2028.
  • 06 Apr 2025 Planned number of patients changed from 160 to 256.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top